Amid efforts in Germany to retool the country’s drug spending, the U.S. is launching an investigation into what the Office of ...
Blue Bell’s Ladder Bio is utilizing molecular technology to help patients move from injected treatments to oral pills.
Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of ...
Senior leaders and scientists from DuPont toured several core facilities and learned about UD’s advanced materials characterization and unique testing capabilities, from analytical techniques for 3D ...
As you all know, Alnylam is pioneering an entirely new class of medicines to treat human disease. This generational technology leverages the mechanism of RNA interference, a natural process of gene ...
IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 June 23, 2026 12:30 PM EDTCompany ParticipantsShaun Bagai - ...
Issued on behalf of Conexeu Sciences Inc.A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a ...
The NRC ascribes a severity level to violations of plant procedures, with five being the least severe and one being the ...
FDA Regulatory Milestone -- sNDA for Ameluz in superficial basal cell carcinoma accepted in February; PDUFA action set for September 28, 2026, positioning Ameluz as potentially the first PDT drug ...
The company recorded a full $16.5 million impairment of an intangible asset due to the Alzheimer's trial not meeting the clinical endpoint. Cory Ellspermann noted the net loss increased to $45.9 ...
The regulatory landscape governing US-China biotech transactions is evolving rapidly on both sides of the Pacific. Multiple legislative ...
Background Chemotherapy-induced cardiotoxicity is a major contributor to long-term cardiovascular morbidity among cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results